INT274892

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.08
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 14
Disease Relevance 1.81
Pain Relevance 1.40

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Dusp6) cytosol (Dusp6) cytoplasm (Dusp6)
Anatomy Link Frequency
microglia 5
Dusp6 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 140 99.56 Very High Very High Very High
Cannabinoid 84 99.40 Very High Very High Very High
antagonist 140 98.92 Very High Very High Very High
Inflammation 294 86.36 High High
Lasting pain 28 84.44 Quite High
Cannabinoid receptor 84 79.84 Quite High
Neuropathic pain 56 78.36 Quite High
Dorsal horn neuron 14 78.32 Quite High
allodynia 28 71.36 Quite High
Peripheral nerve injury 84 70.64 Quite High
Disease Link Frequency Relevance Heat
Cancer 42 90.16 High High
Necrosis 42 89.68 High High
Hypersensitivity 70 89.48 High High
INFLAMMATION 322 86.36 High High
Pain 70 84.44 Quite High
Neuropathic Pain 98 78.36 Quite High
Nervous System Injury 126 73.52 Quite High
Diabetes Mellitus 14 51.28 Quite High
Frailty 28 50.12 Quite High
Drug Induced Neurotoxicity 14 39.64 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
LPS did not significantly change the levels of MKP-3 expression compared to the medium control group at the tested time points (Figures 1B).
Gene_expression (expression) of MKP-3
1) Confidence 0.08 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0.06 Pain Relevance 0.03
MKP-3 expression was significantly increased in LPS + JWH015 at 15 and 60 min incubation time points (1.45 ± 0.14 and 1.42 ± 18 of medium control group respectively, p < 0.05; Figures 1B).
Gene_expression (expression) of MKP-3
2) Confidence 0.08 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0.05 Pain Relevance 0.03
To test whether MKP-1 and MKP-3 are constitutively expressed in microglial cells we incubated primary microglia in serum free medium (DMEM) or in DMEM plus 10% fetal bovine serum (S+DMEM) for 1.5 or 20 h.
Gene_expression (expressed) of MKP-3 in microglia
3) Confidence 0.08 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0 Pain Relevance 0
M) in the absence of JWH015, did not modify the expression of MKP-1, MKP-3, t-ERK and p-ERK when compared to the LPS alone group (data not shown).
Gene_expression (expression) of MKP-3
4) Confidence 0.08 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0 Pain Relevance 0.15
The expression of both MKP-1 and MKP-3 were significantly enhanced in LPS+JWH015 group (p < 0.05) as shown previously.
Gene_expression (expression) of MKP-3
5) Confidence 0.08 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0 Pain Relevance 0.03
This increased MKP-3 expression in LPS + JWH015 group was also significantly different from the LPS alone group at the 15 min incubation time point (15 min, 1.45 ± 0.14 vs. 1 ± 0.07 of medium control group respectively, p < 0.05, Figures 1B).
Gene_expression (expression) of MKP-3
6) Confidence 0.08 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0 Pain Relevance 0
We also confirmed a constitutive expression of MKP-3 in microglia with no differences between DMEM and S+DMEM group or 1.5 and 20 h incubation periods (1.5 hr DMEM vs.
Gene_expression (expression) of MKP-3 in microglia
7) Confidence 0.08 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0 Pain Relevance 0
Additionally, the reduction of LPS-stimulated microglial migration by JWH015 was blocked by triptolide (which also inhibits MKP-3 expression).
Gene_expression (expression) of MKP-3
8) Confidence 0.07 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0.89 Pain Relevance 0.60
Since our results suggest that MKP-3 rather than MKP-1 is responsible for the p-ERK1/2 reduction induced by JWH015, we challenged the effects of JWH015 on MKP-3 expression with specific cannabinoid antagonists.
Gene_expression (expression) of MKP-3 associated with antagonist and cannabinoid
9) Confidence 0.07 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0 Pain Relevance 0.19
We investigated the functional implications of MKP-1 and MKP-3 modulation by studying ERK1/2 phosphorylation.
Gene_expression (modulation) of MKP-3
10) Confidence 0.07 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0 Pain Relevance 0
Unexpectedly, neither PSI2106 nor Ro-31-8220 (which effectively blocked only the JWH015-induced MKP-1 but not MKP-3 expression) modified p-ERK1 (1 ?
Gene_expression (expression) of MKP-3
11) Confidence 0.07 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0 Pain Relevance 0
JWH015 (a CBR2 agonist) increased MKP-1 and MKP-3 expression, which in turn reduced p-ERK1/2 in LPS-stimulated primary microglia.
Gene_expression (expression) of MKP-3 in microglia associated with agonist
12) Confidence 0.06 Published 2009 Journal Mol Pain Section Abstract Doc Link PMC2704199 Disease Relevance 0.34 Pain Relevance 0.21
First, we determined the effects of JWH015 on MKP-1 and MKP-3 expression in LPS-stimulated microglia.
Gene_expression (expression) of MKP-3 in microglia
13) Confidence 0.06 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0.47 Pain Relevance 0.16
M) completely inhibited the JWH015-induced MKP-1 (Figures 3A and 3B) and MKP-3 (Figures 3D and 3E) expression in LPS-stimulated microglia.
Gene_expression (expression) of MKP-3 in microglia
14) Confidence 0.06 Published 2009 Journal Mol Pain Section Body Doc Link PMC2704199 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox